UBS upgrades CVS to buy rating, sees further recovery ahead
UBS analyst Kevin Caliendo's revised price target implies 15% upside ahead for shares of the health care benefit and pharmacy chain.
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.